TCRT Alaunos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRT

Price (delayed)

$2.43

Market cap

$5.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$5.43M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 ...

Highlights
Alaunos Therapeutics's EPS has increased by 16% YoY and by 3.2% from the previous quarter
The company's quick ratio has surged by 97% YoY but it has shrunk by 65% QoQ
TCRT's equity is down by 40% QoQ but it is up by 22% YoY
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The gross profit has dropped by 63% year-on-year and by 40% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ziopharm.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TCRT

TCRT stock price

How has the Alaunos Therapeutics stock price performed over time
Intraday
-7.25%
1 week
-20.59%
1 month
-3.96%
1 year
-9.63%
YTD
-24.77%
QTD
-15.03%

Financial performance

How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$3,000
Gross profit
$3,000
Operating income
-$4.15M
Net income
-$4.11M
Gross margin
100%
Net margin
-136,966.7%
Alaunos Therapeutics's net margin has plunged by 169% YoY and by 64% from the previous quarter
The operating margin has plunged by 165% YoY and by 64% from the previous quarter
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The gross profit has dropped by 63% year-on-year and by 40% since the previous quarter

Price vs fundamentals

How does TCRT's price correlate with its fundamentals

Growth

What is Alaunos Therapeutics's growth rate over time

Valuation

What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
4.49
P/S
1,578.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,808.39
Alaunos Therapeutics's EPS has increased by 16% YoY and by 3.2% from the previous quarter
The price to book (P/B) is 51% higher than the last 4 quarters average of 3.2 and 15% higher than the 5-year quarterly average of 4.2
TCRT's equity is down by 40% QoQ but it is up by 22% YoY
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The price to sales (P/S) is 32% higher than the 5-year quarterly average of 1288.9 and 5% higher than the last 4 quarters average of 1616.0

Efficiency

How efficient is Alaunos Therapeutics business performance
Alaunos Therapeutics's ROS has plunged by 169% YoY and by 64% from the previous quarter
The ROIC fell by 22% YoY but it rose by 7% QoQ
The return on equity has grown by 3.9% since the previous quarter and by 2% year-on-year

Dividends

What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRT.

Financial health

How did Alaunos Therapeutics financials performed over time
The company's quick ratio has surged by 97% YoY but it has shrunk by 65% QoQ
Alaunos Therapeutics's current ratio has soared by 63% YoY but it has decreased by 33% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
TCRT's equity is down by 40% QoQ but it is up by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.